tegobuvir: Clinical Trials

7 trials of tegobuvir, newest first

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

7 completed. 7 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	7	Completed 7

Follow tegobuvir: new trials by email Literature Review of tegobuvir trials Research Report on tegobuvir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection GS-5885 tablet, GS-9451 tablet, tegobuvir capsule - Chronic Genotype 1a or 1b HCV Infection	Phase 2	Completed	Gilead Sciences	163	2011-09-01	2013-12-20
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection GS-5885, GS-9451, tegobuvir - Hepatitis C, Chronic	Phase 2	Completed	Gilead Sciences	170	2011-09-01	2013-12-17
GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection GS-5885, Tegobuvir, GS-9451 - Hepatitis C, Chronic	Phase 2	Completed	Gilead Sciences	141	2011-05-01	2013-12-20
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Tegobuvir (GS-9190), GS-9451, Pegasys® - Hepatitis C, Chronic	Phase 2	Completed	Gilead Sciences	245	2010-10-01	2014-02-06
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C GS-9190, GS-9256, Pegasys® - Chronic Hepatitis C Infection	Phase 2	Completed	Gilead Sciences	324	2010-10-01	2014-01-28
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection GS-9256, GS-9190, Ribavirin - HCV Infection	Phase 2	Completed	Gilead Sciences	46	2010-02-01	2012-05-31
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection placebo, GS-9190, Peginterferon Alfa 2a - HCV Infection	Phase 2	Completed	Gilead Sciences	252	2008-10-01	2013-11-05

Conditions studied

Sponsors

Countries

Top investigators